No Data
China Galaxy Securities: A review of the fifth set of standards on the Star has significantly boosted investment in the pharmaceutical industry.
Future reforms in diversified payment for commercial insurance are expected to bring marginal improvements from a policy perspective, and there are good long-term investment opportunities in pharmaceutical innovation and related industries.
U.S. FDA Granted Priority Review to Dizal's Sunvozertinib New Drug Application
Dizhe Pharmaceutical (688192.SH): The上市申请 of Shuwotini has been accepted by the USA FDA and has obtained priority review designation.
On January 7, Gelonghui reported that Dizhe Pharmaceutical (688192.SH) announced that its self-developed Suvoletin Tablets (trade name: Suvozhe, hereinafter referred to as "Suvoletin") new drug application (New Drug Application, NDA) has passed the filing review by the FDA and has been granted Priority Review Designation, for patients who have previously experienced disease progression during or after platinum-based chemotherapy, and for which the presence of epidermal is confirmed by FDA-approved assay kits.
Here's Why Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Can Afford Some Debt
Approximately 57.4518 million restricted shares of Dize Pharmaceutical (688192.SH) will be available for trading starting from January 9.
Dizhe Pharmaceutical (688192.SH) announced that the restricted shares for circulation in this listing are part of the company's initial public offering...
Kaiyuan Securities: Each subtype of hematological tumors has the potential to hatch "heavyweight bomb" drugs. Pay attention to Innovative Drugs companies.
The subtype of blood tumors is less aggressive with a longer treatment cycle, generally requiring long-term medication. Patients have relatively high viscosity and the potential for the emergence of "blockbuster" drugs.
